Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Maryland for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Maryland only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Maryland (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Jason Taksey (NPI 1316017676)

Field	Value
Entity Type	Individual
Organization	Jason Taksey
Address	2003 Medical Pkwy
City	Annapolis
State	MD
ZIP	21401
Taxonomy	Medical Oncology Physician
NPI Enumerated	November 8, 2006

Payer Source	Total Paid
Medicare	$3.3M
Medicaid	$0

Key Findings

This provider’s billed activity is almost entirely Medicare-based: total Medicare revenue is $3.3M while Medicaid revenue is none, so the profile is effectively single‑payer (Medicare) with no Medicaid billing on file. That concentration means analyses of utilization and revenue exposure should focus on Medicare payment and policy changes rather than Medicaid trends.

Revenue is highly concentrated in a handful of drug codes: the precomputed top three Medicare codes account for 83.7% of this provider’s Medicare revenue, driven by J9271 at 50.6%, J9299 at 29.5%, and J0897 at 3.5%. This concentration indicates that a very small set of high‑cost oncology drugs dominates the financial picture.

The mix of high‑revenue items and procedure codes indicates a specialty oncology infusion practice: large volumes of J9271 (pembrolizumab) and J9299 (nivolumab) combined with chemotherapy administration codes such as 96413 and infusion/IV codes like 96365 point to routine outpatient infusion services paired with concurrent E/M visits. Supportive and adjunctive agents such as J0897 (denosumab) and J0881 (darbepoetin alfa) further signal comprehensive oncology management (tumor‑directed therapy plus bone health and anemia management).

Competitive standing for key immunotherapy agents is nationally prominent: J9271 ranks #35 of 1841 providers nationally (98th percentile; notably above typical national volume) and J9299 ranks #29 of 505 providers nationally (94th percentile; notably above typical national volume). These rank/percentile positions indicate the provider is a major national-volume reporter for these agents rather than a modest user.

Operational throughput is substantial across both drug administration and office care: J9271 shows 38.4K claims and J9299 shows 41.9K claims, while the E/M code 99214 appears with 1.1K claims and is labeled an extreme outlier, far above typical national volume. High percentiles for chemotherapy administration (96413 at the 97th percentile, described as notably above typical national volume) reinforce that this practice delivers large volumes of infused oncology therapy alongside significant office‑based management.

Beyond the two leading immunotherapies, several other drug codes show above‑typical national volume: J0185 (aprepitant) ranks #50 of 819 (94th percentile; notably above typical national volume), J9171 (docetaxel) ranks #10 of 207 (96th percentile; notably above typical national volume), and J9201 (gemcitabine) ranks #18 of 631 (97th percentile; notably above typical national volume). This pattern suggests the practice manages a diversified portfolio of systemic oncology agents, not exclusively a single drug class.

The provider’s financial reliance on a narrow set of high‑revenue drugs (top three = 83.7%) creates concentrated exposure to changes in drug utilization, reimbursement, or payer coverage policies for those agents. From a payer or network perspective, this profile signals that shifts in immunotherapy access or site‑of‑care reimbursement could materially affect this provider’s Medicare revenue stream.

The NPI was enumerated on 2006-11-08 (~20 years ago), indicating a long‑tenured practice. Coupled with the high volumes and national percentile rankings on multiple oncology drugs, this tenure supports the interpretation of an established oncology infusion operation in Annapolis, MD rather than a new or occasional oncology provider.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

57 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	38,400	$40	$1.7M
J9299	Injection, nivolumab, 1 mg	41,880	$20	$963.2K
J0897	Injection, denosumab, 1 mg	6,420	$20	$115.6K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,070	$100	$104.6K
J1437	Injection, ferric derisomaltose, 10 mg	5,200	$20	$88.4K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	750	$110	$80.5K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	20,100	$1	$40.2K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	450	$70	$31.8K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	230	$130	$30.1K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	160	$140	$23.6K

Showing 1–10 of 57

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 57 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Maryland Distribution

Jason Taksey — 4 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Maryland

Full comparison — all codes billed, vs. state median

57 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	4	60	15,000	$40	$787.6K
J9299	3	20	24,080	$20	$660.6K
J0897	108	340	3,600	$20	$114.4K
J0881	40	60	30,420	$1	$76.4K
J1437	13	50	2,800	$20	$75.1K
J3490	40	100	70	$450	$62.1K
96413	14	230	200	$110	$29.6K
J9217	23	100	150	$130	$27.3K
99214	471	10,270	150	$90	$24.1K
J0185	2	40	9,230	$1	$15.1K

Showing 1–10 of 57

Related Providers

Other providers that share a Tax Identification Number (TIN) with Jason Taksey, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Luminis Health Doctors Community Medical Center, Inc.	MD	General Acute Care Hospital	$0	$9.9M
Maryland Oncology Hematology P.A.	MD	Hematology & Oncology Physician	$0	$4.6M
Kashif Ali	MD	Hematology & Oncology Physician	$3.6M	$0
Andrew Mener	MD	Hematology & Oncology Physician	$3.5M	$0
Frederick Min	MD	Hematology & Oncology Physician	$3.2M	$0
Mohit Narang	MD	Medical Oncology Physician	$3M	$0
Frederick Smith	MD	Medical Oncology Physician	$2.7M	$0
Deepnarayan Tiwarri	MD	Hematology & Oncology Physician	$2.6M	$0
Amr Hegazi	MD	Hematology & Oncology Physician	$2.3M	$0
Edward Lee	MD	Medical Oncology Physician	$1.9M	$0

Nearby Providers

Other providers in the same ZIP code as Jason Taksey, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Anne Arundel County Public Schools	MD	Local Education Agency (LEA)	$0	$47.7M
Advanced Pain Management Specialists, LLC	MD	Interventional Pain Medicine Physician	$0	$33.8M
Luminis Health Pathways, Inc.	MD	Adult Mental Health Clinic/Center	$0	$14.4M
Bay Clinical Laboratories	MD	Clinical Medical Laboratory	$104.9K	$9.7M
Wellspring Therapy Services, LLC	MD	Early Intervention Provider Agency	$0	$9.3M
Doctors Emergency Service, PA	MD	Emergency Medicine Physician	$0	$9.2M
New Journey, Inc.	MD	Methadone Clinic	$188.3K	$8.6M
Committed To Change,p.c.	MD	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$7.9M
Psychotherapeutic Treatment Services	MD	Mental Illness Community Based Residential Treatment Facility	$0	$7.6M
Advocate Support Services, Inc.	MD	Community/Behavioral Health Agency	$0	$7.4M

Jason Taksey — Billing Profile & Reimbursement Data

Sign up for Jason Taksey — Billing Profile & Reimbursement Data policy alerts

Jason Taksey — Billing Profile & Reimbursement Data

Sign up for Jason Taksey — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References